期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 15, 期 6, 页码 709-719出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.15.6.709
关键词
farnesyl transferase inhibitor; lonafarnib; Ras; SCH-66336; targeted therapy
资金
- NCI NIH HHS [R01 CA100816, R01 CA109520] Funding Source: Medline
Farnesyl transferase inhibitors (FTIs) are anticancer agents that were designed to block the post-translational attachment of the prenyl moiety to C-terminal cysteine residue of Ras and thus inactivate it. Because Ras plays an important role in tumour progression and the ras mutation is one of the most frequent aberrations in cancer, FTIs have been expected to exert excellent therapeutic activities. Phase I and 11 clinical trials confirmed relevant antitumour activity and low toxicity; however, no improvement in overall survival has been reported in Phase III trials. The exact mechanism of action of this class of agents is currently unknown. Increasing lines of evidence indicate that the cytotoxic actions of FTIs are not due to the inhibition of Ras proteins exclusively, but to the modulation of other targets, including RhoB, the centromere-binding proteins and other proteins that have not yet been identified. This review describes the pharmacological and clinical data as well as mechanisms of action of FTIs, especially lona-farnib (SCH-66336), a non-peptidomimetic inhibitor that has shown anticancer activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据